SAN DIEGO--(BUSINESS WIRE)--Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data from studies of its lead antifungal rezafungin will be presented at the 2018 Hot Topics in Infectious Diseases (HTIDE) Conference to be held in Mestre, Venice from October 25-26, 2018. Rezafungin is the only once-weekly antifungal product candidate in development for the treatment and prevention of life-threatening invasive fungal infections.
A total of three rezafungin abstracts have been accepted for poster presentations. Two posters will highlight analyses of rezafungin in special patient populations and by geographic outcomes based on results from Cidara’s Phase 2 STRIVE trial. The third poster will highlight the in vivo efficacy of rezafungin in aspergillosis.
Hot Topics in Infectious Diseases (HTIDE) is a bi-annual conference which convenes more than 400 delegates from all over the world to discuss topics on novel approaches to diagnosis and treatment of infectious diseases. Cidara’s HTIDE posters will be on display throughout the conference and featured in a poster walk discussion during the lunch session on both days. Details are as follows:
Title: Rezafungin for the Treatment of Candidemia and/or Invasive
Candidiasis: Analysis of the Global, Randomized, Double-Blind,
Placebo-Controlled Phase 2 STRIVE Clinical Trial by Geographic Region of
Author: T. Sandison, et. al.
Title: Analysis of Patients by Baseline Renal Function from the Phase 2
STRIVE Clinical Trial of Rezafungin for the Treatment of Candidemia
and/or Invasive Candidiasis
Author: S. Flanagan, et. al.
Title: Of Mice and Men: Comparison of Rezafungin versus Micafungin Lung
Exposures in Mouse, and Potential Implications for Human ELF and
Author: V. Ong, et. al.
Copies of these presentations will be available on the Cidara website following the meeting: www.cidara.com.
Rezafungin is a novel antifungal echinocandin being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. Rezafungin has a unique pharmacokinetic profile with a prolonged half-life and front-loaded plasma exposure which, in contrast to all other echinocandins, allows for once-weekly IV therapy. Rezafungin is being studied to address unmet needs in the treatment of candidemia and invasive candidiasis as well as for prophylaxis (prevention) of invasive fungal infections, including Candida, Aspergillus and Pneumocystis in patients undergoing allogeneic bone marrow transplantation.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical trial in the treatment of candidemia and invasive candidiasis and plans to initiate a second Phase 3 trial in the prophylaxis of invasive fungal infections. Rezafungin has improved pharmacokinetics compared to existing echinocandins and the potential for expanded utility across patient settings. It is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. Cidara also is leveraging its novel Cloudbreak™ platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the first immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the initiation of rezafungin Phase 3 pivotal trials, the potential for rezafungin to be a novel treatment and prophylactic agent against deadly invasive fungal infections, and rezafungin’s potential for expanded utility across patient settings. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; changes in Cidara’s plans to develop and commercialize its product candidates; Cidara’s ability to obtain additional financing; Cidara’s ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Cidara’s Form 10-Q most recently filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.